Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, de la Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Bladé J, Perez-Simon JA, San Miguel JF; Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood. 2016 Mar 3;127(9):1151-62. doi: 10.1182/blood-2015-10-662320. Epub 2015 Dec 14. PubMed PMID: 26668134.
AÑO: 2016; IF: 13.164
26668134
Plasencia-Martínez JM, Carmona-Bayonas A, Calvo-Temprano D, Jiménez-Fonseca P. Prognostic value of computed tomography in acute pulmonary thromboembolism. Radiologia. 2016 Sep-Oct;58(5):391-403. doi: 10.1016/j.rx.2016.06.011. Epub 2016 Aug 1. Review. English, Spanish. PubMed PMID: 27492053.
AÑO: 2016
27492053
O'Sullivan JM, Aguila S, McRae E, Ward SE, Rawley O, Fallon PG, Brophy TM, Preston RJ, Brady L, Sheils O, Chion A, O'Donnell JS. N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. J Thromb Haemost. 2016 Dec;14(12):2446-2457. doi: 10.1111/jth.13537. Epub 2016 Dec 9. PubMed PMID: 27732771.
AÑO: 2016; IF: 16.036
27732771
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12. PubMed PMID: 27175028; PubMed Central PMCID: PMC4967571.
AÑO: 2016; IF: 7.702
27175028
Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016 Dec;95(12):2033-2041. Epub 2016 Oct 14. PubMed PMID: 27738789.
AÑO: 2016; IF: 3.083
27738789
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL